Key result
A single 4 mg oral dose of reboxetine significantly increased cortisol release at 1.5 hours compared to placebo, with males showing a significantly greater response than females.
Why the study?
Does a single oral dose of reboxetine increase cortisol response in healthy volunteers compared to placebo?
RCT (n=40)
double-blind
randomly allocated
Does a single oral dose of reboxetine increase cortisol response in healthy volunteers compared to placebo?
A single oral dose of reboxetine increases cortisol release in healthy volunteers, with a more pronounced response in men than women.
4 mg reboxetine acutely raises cortisol in healthy volunteers; leaves open its value as a noradrenergic probe in clinical populations.
This study examined the cortisol response to reboxetine in a sample of healthy men and women. Forty healthy volunteers were randomly allocated to one of two treatment groups: placebo or 4 mg reboxetine under double-blind conditions. Saliva cortisol was measured pre, 1 and 1.5 h post-treatment. Mood and side-effects were also measured. A single oral dose of 4 mg reboxetine did not affect positive or negative mood but did produce some side-effects. It was also sufficient to increase cortisol release 1.5 h post-treatment compared to placebo. In addition, reboxetine lead to a significantly increased cortisol release in male compared to female volunteers. The results suggest that healthy male volunteers are more responsive to challenge with a noradrenergic compound than females.
No takes yet. Share an insight, caveat, or question.
Tse et al. (2005) conducted an RCT in healthy (n=40). reboxetine vs. placebo was evaluated on cortisol release 1.5 h post-treatment. A single 4 mg oral dose of reboxetine significantly increased cortisol release at 1.5 hours compared to placebo, with males showing a significantly greater response than females.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: